This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Rik Roelandts, MD
Department of Dermatology University of Leuven Brusselsestraat 69 B-3000 Leuven, Belgium

Maurits Van Boven, DSc; Hendrik De Greef, PhD; Renaat Kinget, PhD; Paul Adriaens, PhD; Paul Daenens, DSc
University of Leuven

Arch Dermatol. 1984;120(10):1281-1282.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Treatment failure of psoralens and UV-A (PUVA) therapy for psoriasis may result from an inappropriate methoxsalen plasma concentration when the UV-A irradiation is actually administered.¹ Indeed, there seems to be a good correlation between the methoxsalen skin concentration and the plasma concentration.^2,3 Significant interindividual and intraindividual differences occur in these plasma levels, which must be standardized and optimized as far as possible if PUVA therapy is to be adequately planned and evaluated.

Because major differences occur in the maximum plasma levels as well as in the time when the maximum concentrations occur as a function of the formulation or the brand of methoxsalen, we compared the pharmacokinetics of 12 different methoxsalen brands and formulations. Seven of them were commercially available brands. The other five were self-prepared formulations: oil-in-water emulsion with 20% oil, oil-in-water emulsion with 40% oil, lipo capsules (vegetable oil plus wax), lipoleci capsules . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?